SVB Leerink Downgrades Decibel Therapeutics to Market Perform, Lowers Price Target to $2
SVB Leerink analyst Mani Foroohar downgrades Decibel Therapeutics (NASDAQ:DBTX) from Outperform to Market Perform and lowers the price target from $7 to $2.